Navigation Links
Vascular Flow Appoints Jonathan Sackier to Board
Date:4/8/2013

DUNDEE, Scotland, April 8, 2013 /PRNewswire/ --

Professor Jonathan M Sackier has joined Vascular Flow Technologies, a global medical device company based in Dundee, Scotland as a Non-Executive Board Member. Professor Sackier is an internationally recognised surgeon, business consultant and media contributor.

Vascular Flow Technologies (VF)

VF is a young global medical devices company focused on the research, development and commercialisation of vascular devices based on a new understanding of blood flow dynamics - Spiral Laminar Flow™ - first observed by Leonardo Da Vinci in the 15th Century. They are based in Dundee, Scotland and a US division in Boston, Massachusetts. Their innovative technology is currently applied to two synthetic vascular grafts, the SLF™ PV graft and SLF™ AV graft.

Professor Jonathan M Sackier

Professor Sackier was appointed to the board of VF on 3rd April 2013 and will bring a wealth of knowledge, experience and drive to the company. He trained in Britain as a surgeon then moved to the USA where he helped lead the laparoscopic surgery revolution and founded the Washington Institute of Surgical Endoscopy.

He is Visiting Professor of Surgery and Medicine at the University of Virginia  and his activities in research, funded by multiple grants, have led to many publications, chapters and books. He has served journals in editorial or reviewer functions, been involved in medical societies at the highest level and been honoured for his work in many countries.

Jonathan's collaborations with the pharmaceutical and medical device industry have led to multiple technologies coming to market. He has acted as a consultant to healthcare companies, participated in raisi
'/>"/>

SOURCE Vascular Flow Technologies
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAQUET Medical Systems USA Launches The MIRA-i CS Retractor System For Use During Minimally Invasive Revascularization Procedures
2. Valencia College Utilizes Sophisticated Simbonix Simulators in Their Cardiovascular Technology (CVT) Training Program
3. Positive Data, Pipeline Improvements & Market Expansion - Research Report on Abbott Laboratories, Stryker Corporation, St. Jude Medical, Cardiovascular Systems and MAKO Surgical
4. Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
5. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
6. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
7. Terumo Medical Corporation Files Patent Infringement Lawsuit Against Vascular Solutions And Lepu Medical Technology Company
8. Interventional Cardiologists Cautious in Adopting Intravascular Imaging and Assessment Devices: Challenge to Manufacturers
9. QualiMed Innovative Medizinprodukte GmbH, Based in Winsen Germany has Received Notice of CE Approval for its Line of Peripheral Balloons for the Treatment of Peripheral Vascular Obstructions
10. IDEV Announces Results from Revascularization with Supera on Real World Patients (RESTORE) Study, Demonstrating Positive Clinical Outcomes in Significantly Diseased Patients with Long Lesions
11. Sanofi Launches Breakthrough Technology for Cardiovascular and Vascular Surgery Procedures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... , ENGLEWOOD, Colo., Dec. 7 ... DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting (MCM). ... safety and pharmacy efficiency through the management of IV ... into current pharmacy practice and techniques, while providing a ...
... , CARLSBAD, Calif., Dec. 7 Genoptix, Inc. (Nasdaq: ... the Company,s participation at the Deutsche Bank 2009 MedTools Investor ... Mass. on December 9-10, 2009. , Genoptix,s EVP ... the Company on Wednesday, December 9, 2009. He will ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... Santa Clara, CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 ... The National Football League’s biggest day each year is the Super Bowl. In the ... buildup that takes place from the host venue. The 2016 Super Bowl game will mark ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last ... by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , ... are customizable. The best part: whenever a product is purchased, the Meso Foundation ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... the FDA could be one of the most significant advances in ... say doctors involved in the research., ,Diabetes is a disease ... body (type 1 diabetes) or the body does not effectively use ... another hormone -- amylin -- to aid in the treatment of ...
... survey is a worldwide investigation of sociocultural and political ... network of social scientists. It includes questions about how ... their lives. ,It showed that average happiness has ... War II, although incomes have risen. ,The analysis ...
... death in many people, but previous research has not looked ... study focuses on depression in elderly people living in the ... ,The study, involved 250 participants in a community health program. ... of depression and then did so again at 18 months. ...
... care unit patients who receive a preventative round of antibiotics ... more likely to survive their ICU stay. // ... between ICU patients who were given antibiotics and those who ... antibiotics to kill harmful bacteria in the mouth, stomach, and ...
... be at risk for experiencing dangerous falls. ,Researchers studied more ... asked if they // had fallen in the last 12 months, ... medical attention for the falls. ,They also brought all ... history report. ,Results of the study show nearly three ...
... receives for breast cancer be putting her at higher ... ,Studies finds women who underwent simple mastectomy and radiotherapy ... had a radical mastectomy and no radiotherapy to later ... cancer rates were noted among a group of women ...
Cached Medicine News:Health News:ICU Survival can be improved by Antibiotic use 2
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
... new Contrast Agent for Ultrasonography ... stabilized SF6 microbubbles. The size ... 1 and 10 m, and ... and 5 x 108 per ...
... VISIPAQUE is the only isosmolar contrast medium (IOCM) ... to that of blood, VISIPAQUE was designed for ... only contrast medium formulated with sodium and calcium ... VISIPAQUE received FDA approval for use in children ...
... (iopromide) injection is a nonionic, iodinated, ... administration. Introduced in the U.S. in ... in Europe, ULTRAVIST today is ... has established a positive clinical experience ...
Medicine Products: